Key result
Medication non-retrieval is linked to a ~42% lower chance of achieving LDL-C control versus adherence.
Why the study?
Poorly controlled cardiometabolic biometric measures are mediated by medication adherence and clinician-level therapeutic inertia, but studies comparing the relative contribution of these two factors to disease control are lacking.
Do therapeutic inertia and medication non-adherence independently reduce the likelihood of achieving biometric control in primary care patients with cardiometabolic diseases?
Cohort (n=92,766)
No
Do therapeutic inertia and medication non-adherence independently reduce the likelihood of achieving biometric control in primary care patients with cardiometabolic diseases?
Effect estimate: HR 0.58 (95% CI 0.55–0.60)
Therapeutic inertia has a substantially greater impact on the persistence of cardiometabolic health gaps, particularly for LDL-C, than patient medication non-adherence.
No takes yet. Share an insight, caveat, or question.
Non-adherence was associated with poorer LDL-C control; hypothesis-generating for therapeutic inertia's greater impact, needing prospective confirmation.
Yan et al. (2022) conducted a cohort in Cardiometabolic diseases (hypertension, dyslipidemia, diabetes) (n=92,766). Patients who did not retrieve their medication were 42% less likely to achieve LDL-C control compared to those who adhered to their medication regimen (HR 0.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: